ALK

Allergy solutions for life

Take back control

More than 500 million people worldwide have allergies. Many of them suffer in silence because the way ahead is too confusing.

allergy_solutions_for_life

Watch the video

News

See all

Post date
09/02/2019

Germany becomes first launch market for ALK’s tree SLIT-tablet

Read more
Post date
08/30/2019

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

Read more
Post date
08/13/2019

Six-month interim report (Q2) 2019

Read more
Post date
08/12/2019

ALK upgrades its full-year financial outlook due to strong growth

Read more
Post date
08/09/2019

ALK announces new epinephrine auto-injector strategy based on innovative new product for the USA

Read more
Post date
08/06/2019

Release date of six-month interim report (Q2) 2019 for ALK and audio cast

Read more
Post date
06/24/2019

ALK submits registration application for tree SLIT-tablet in Canada

Read more
Post date
06/07/2019

ALK obtains European approval for its tree SLIT-tablet against allergic rhinitis

Read more
Post date
06/04/2019

As ALK prepares to further extend their SLIT-tablet portfolio, tablet formulation is seen as key in delivering consistent positive clinical trial results

Read more

ALK launches growth strategy

Transformational strategy to redefine ALK's position in the global allergy market and stimulate a new era of growth for the company.

Kornel Golebski wins allergy research award

Dr. Kornel Golebski from the Department of Pulmonology and Experimental Immunology, Amsterdam UMC, University of Amsterdam, has been honoured with the ARIA-EUFOREA Henning Løwenstein Research Award 2019. The prestigious ARIA-EUFOREA Henning Løwenstein Research Award is given to a young researcher, who has shown excellence in the field of allergy, every second year in a collaboration between ALK and the European Forum for Research and Education in Allergy and Airway diseases (EUFOREA).

Henning Løwenstein Research Award 2019

ALK in brief

Allergy at a glance

Allergic rhinitis - popularly known as hay fever - is a widespread chronic disease. It is estimated to affect one in four persons in the industrialised world.

Our solutions

By collecting information and the latest and most trusted solutions together in one place, we want to make allergy surprisingly simple to manage.